BRTX-100 is intended for the treatment of chronic lumber disc disease. Credit: Sasun Bughdaryan on Unsplash.

Northwell Health and Northwell’s Feinstein Institutes for Medical Research have entered into a clinical trial agreement to participate in BioRestorative Therapies’ Phase II clinical trial of BRTX-100 for the treatment of chronic lumber disc disease (cLDD).

A new cell-based therapeutic, BRTX-100 is designed to target areas of the body having little blood flow.

Related Company Profiles

View all

An office-based injection procedural approach of BRTX-100 introduces patient’s own cultured mesenchymal stem cells to target the harsh environment of the intervertebral disc.

Designed to assess the preliminary efficacy and safety of a single dose of BRTX-100, the double-blinded, randomised, controlled, and prospective study will enrol a total of around 99 patients.

Subjects selected at up to 15 US clinical sites will be randomised into 2:1 ratio to receive either BRTX-100 or control.

See Also:

BioRestorative CEO Lance Alstodt said: “We are delighted to enter into such an agreement with Northwell and their world class team of non-surgical and surgical spine clinicians and researchers across the disciplines.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We hope to identify other areas where our two organisations can work closely with one another. Research is a very obvious area of focus for both of us and we look forward to exploring strategic possibilities to enhance and strengthen our relationship with Northwell.”

BioRestorative’s cell-based therapy candidate ThermoStem uses brown adipose derived stem cells to target obesity and metabolic disorders.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.